ATE248835T1 - Prodrugs von impdh-inhibierenden carbamaten - Google Patents

Prodrugs von impdh-inhibierenden carbamaten

Info

Publication number
ATE248835T1
ATE248835T1 AT00950246T AT00950246T ATE248835T1 AT E248835 T1 ATE248835 T1 AT E248835T1 AT 00950246 T AT00950246 T AT 00950246T AT 00950246 T AT00950246 T AT 00950246T AT E248835 T1 ATE248835 T1 AT E248835T1
Authority
AT
Austria
Prior art keywords
compounds
impdh
prodrugs
inhibiting
carbamates
Prior art date
Application number
AT00950246T
Other languages
English (en)
Inventor
Dean P Stamos
Randy S Bethiel
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE248835T1 publication Critical patent/ATE248835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00950246T 1999-06-25 2000-06-23 Prodrugs von impdh-inhibierenden carbamaten ATE248835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14110299P 1999-06-25 1999-06-25
PCT/US2000/017400 WO2001000622A1 (en) 1999-06-25 2000-06-23 Prodrugs of carbamate inhibitors of impdh

Publications (1)

Publication Number Publication Date
ATE248835T1 true ATE248835T1 (de) 2003-09-15

Family

ID=22494164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950246T ATE248835T1 (de) 1999-06-25 2000-06-23 Prodrugs von impdh-inhibierenden carbamaten

Country Status (12)

Country Link
US (4) US6395763B1 (de)
EP (1) EP1196414B1 (de)
JP (1) JP4773010B2 (de)
AT (1) ATE248835T1 (de)
AU (1) AU780973B2 (de)
CA (1) CA2377278C (de)
DE (1) DE60005017T2 (de)
DK (1) DK1196414T3 (de)
ES (1) ES2200902T3 (de)
MX (1) MXPA02000294A (de)
PT (1) PT1196414E (de)
WO (1) WO2001000622A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301802B6 (cs) * 1999-03-19 2010-06-30 Vertex Pharmaceuticals Incorporated Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem
PT1196414E (pt) 1999-06-25 2003-12-31 Vertex Pharma Pro-farmacos de inibidores carbamato de impdh
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
WO2004012746A2 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
SG182849A1 (en) * 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
EP1620109A2 (de) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhbitor phosphonat konjugate
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
BRPI0417988A (pt) * 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
EP1809277A2 (de) * 2004-10-26 2007-07-25 Inc. Gilead Sciences Phosphonatderivate aus mycophenolsäure
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
DE102006007146A1 (de) * 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Hcvns3プロテアーゼ阻害剤
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
DE102007032344A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Prodrug-Derivate von 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-carboxamid
DE102007032345A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102007032347A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
WO2009100135A2 (en) * 2008-02-04 2009-08-13 Medical College Georgia Research Institute, Inc. Hla-g compositions and methods of use thereof
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
ES2392611T3 (es) 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
WO2014043380A1 (en) 2012-09-14 2014-03-20 Ligand Pharmaceuticals Incorporated Novel nucleotide prodrug compounds and use
WO2015077368A1 (en) 2013-11-22 2015-05-28 Ligand Pharmaceuticals Incorporated Derivatives of uridine 5'-cyclophosphate useful to treat hepatitis c viral infections
EP3623364A1 (de) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Organische verbindungen und deren verwendungen
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
EP3773579A4 (de) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. Zusammensetzungen und verfahren zur hemmung der dihydroorotatdehydrogenase
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1332306A (en) * 1969-12-23 1973-10-03 Glaxo Lab Ltd Antibiotics
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4892873A (en) * 1985-10-31 1990-01-09 American Cyanamid Company N-substituted -N-(3-(1,2,4-triazolo-(4,3-b)pyridazin-6-yl)phenyl)alkanamides, carbamates and ureas
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
IT1226727B (it) * 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
FR2644462B1 (fr) * 1988-09-23 1993-07-09 Ire Celltarg Sa Nouveaux composes actifs sur les formes tissulaires de la malaria et procede de preparation
US4942226A (en) 1988-12-29 1990-07-17 Merck & Co., Inc. Halogenated pyrimidine nucleosides and their derivatives
US5495047A (en) 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
US5534632A (en) 1991-09-05 1996-07-09 Abbott Laboratories Macrocyclic carbamate immunomodulators
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994012184A1 (en) 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5444072A (en) 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5380879A (en) 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5576313A (en) 1994-08-29 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) * 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
PT1196414E (pt) 1999-06-25 2003-12-31 Vertex Pharma Pro-farmacos de inibidores carbamato de impdh

Also Published As

Publication number Publication date
US6395763B1 (en) 2002-05-28
EP1196414A1 (de) 2002-04-17
ES2200902T3 (es) 2004-03-16
PT1196414E (pt) 2003-12-31
US7777069B2 (en) 2010-08-17
JP4773010B2 (ja) 2011-09-14
JP2003503408A (ja) 2003-01-28
AU780973B2 (en) 2005-04-28
US20020161038A1 (en) 2002-10-31
US20050101664A1 (en) 2005-05-12
CA2377278A1 (en) 2001-01-04
DE60005017D1 (de) 2003-10-09
AU6337400A (en) 2001-01-31
DE60005017T2 (de) 2004-06-09
CA2377278C (en) 2010-03-23
US20090093639A1 (en) 2009-04-09
EP1196414B1 (de) 2003-09-03
MXPA02000294A (es) 2002-06-21
DK1196414T3 (da) 2003-11-24
US6825224B2 (en) 2004-11-30
WO2001000622A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
DE60005017D1 (de) Prodrugs von impdh-inhibierenden carbamaten
AP1498A (en) Inhibitors of impdh enzyme.
PT966465E (pt) Inibidores do enzima imfdh
TR199802136T2 (xx) �MPDH enzimi inhibit�rleri olarak �re t�revleri.
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
PT927161E (pt) Aminas ciclicas substituidas inibidoras de metaloproteases
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
BG104780A (en) Inhibitors of phospholipase enzymes
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
DK1611088T3 (da) Hydroxymater som terapeutiske midler
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
TR200102523T2 (tr) Alkenil ve alkinil içeren metaloproteaz inhibitörleri
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
BR9811348A (pt) Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.
GEP20033130B (en) Inhibitors of IMPDH Enzyme
BR0109354A (pt) Inibidores de metaloproteases os quais contêm cadeias laterais carbocìclicas
DE60318467D1 (de) Pomolsäure zur behandlung von mehrfachresistenten tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196414

Country of ref document: EP